Impact Of Medimmune Case

Introduction The MedImmune case[1] arose when MedImmune, a pharmaceutical manufacturing company, challenged the validity of Cabilly patent II granted to Genentech, a biotechnology corporation. MedImmune had signed an agreement with Genentech, which was the patent holder, to license the Cabilly I patent and the then-pending Cabilly II patent application, entitling MedImmune to make, use, and sell […]